[go: up one dir, main page]

ZA200803208B - Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 - Google Patents

Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38

Info

Publication number
ZA200803208B
ZA200803208B ZA200803208A ZA200803208A ZA200803208B ZA 200803208 B ZA200803208 B ZA 200803208B ZA 200803208 A ZA200803208 A ZA 200803208A ZA 200803208 A ZA200803208 A ZA 200803208A ZA 200803208 B ZA200803208 B ZA 200803208B
Authority
ZA
South Africa
Prior art keywords
human
profiling
generation
antibodies specific
therapeutic antibodies
Prior art date
Application number
ZA200803208A
Other languages
English (en)
Inventor
Tesar Michael
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of ZA200803208B publication Critical patent/ZA200803208B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
ZA200803208A 2005-10-12 2008-04-11 Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 ZA200803208B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72529705P 2005-10-12 2005-10-12

Publications (1)

Publication Number Publication Date
ZA200803208B true ZA200803208B (en) 2009-02-25

Family

ID=37467440

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200803208A ZA200803208B (en) 2005-10-12 2008-04-11 Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38

Country Status (28)

Country Link
US (7) US8088896B2 (xx)
EP (3) EP1945671A2 (xx)
JP (2) JP5362359B2 (xx)
KR (4) KR101574920B1 (xx)
CN (4) CN103554259B (xx)
AR (2) AR055191A1 (xx)
AU (1) AU2006301446B2 (xx)
BR (1) BRPI0618399B1 (xx)
CA (1) CA2625681C (xx)
CY (1) CY1119722T1 (xx)
DK (1) DK2860192T3 (xx)
ES (1) ES2653664T3 (xx)
HR (1) HRP20171978T1 (xx)
HU (1) HUE035250T2 (xx)
IL (1) IL190665B (xx)
LT (1) LT2860192T (xx)
ME (1) ME02886B (xx)
NO (1) NO344961B1 (xx)
NZ (1) NZ566915A (xx)
PL (1) PL2860192T3 (xx)
PT (1) PT2860192T (xx)
RS (1) RS56677B1 (xx)
RU (1) RU2425841C2 (xx)
SG (1) SG10201400973XA (xx)
SI (1) SI2860192T1 (xx)
TW (1) TWI428444B (xx)
WO (1) WO2007042309A2 (xx)
ZA (1) ZA200803208B (xx)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JP5362359B2 (ja) 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
CN103396487A (zh) 2008-12-12 2013-11-20 贝林格尔.英格海姆国际有限公司 抗igf抗体
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
LT2621531T (lt) 2010-09-27 2017-04-10 Morphosys Ag Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2013010955A1 (en) * 2011-07-15 2013-01-24 Morphosys Ag Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US20130122005A1 (en) 2011-10-27 2013-05-16 Paul Adam Anticancer combination therapy
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
CA2859493A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
CA2871417C (en) * 2012-04-23 2021-08-31 Genefrontier Corporation Anti-human cd69 antibody, and use thereof for medical purposes
HUE036518T2 (hu) * 2012-09-25 2018-07-30 Morphosys Ag Kombinációk és alkalmazásaik
DK2914302T3 (en) 2012-11-05 2017-04-10 Morphosys Ag RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
US9845364B2 (en) 2012-11-09 2017-12-19 Genefrontier Corporation Anti-ADAM28 antibody for treating cancer
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
SG11201506956TA (en) * 2013-03-13 2015-10-29 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ES2774976T3 (es) * 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
JP5892117B2 (ja) * 2013-07-17 2016-03-23 横河電機株式会社 フィールド機器及び通信システム
CN103513040B (zh) * 2013-10-16 2015-03-11 常晓天 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
BR112017002136A2 (pt) 2014-08-03 2017-11-21 Pogotec Inc ?sistema de dispositivo eletrônico?
MY192918A (en) 2014-09-09 2022-09-15 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
CN116333153A (zh) 2014-11-26 2023-06-27 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3227338A4 (en) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
EP3266799A4 (en) 2015-03-06 2018-09-12 GeneFrontier Corporation Anti-human membrane-type adam28 antibody
WO2016164656A1 (en) * 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
HRP20210552T1 (hr) 2015-05-13 2021-05-14 Morphosys Ag Liječenje multiplog mijeloma (mm)
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
MY192978A (en) * 2015-06-22 2022-09-20 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HUE066300T2 (hu) 2015-06-24 2024-07-28 Janssen Biotech Inc Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
PL3827845T3 (pl) 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
AU2017226960B2 (en) 2016-03-04 2024-03-21 Morphosys Ag Clinical assessment of M-protein response in multiple myeloma
CA3018272A1 (en) 2016-04-22 2017-10-26 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
BR112019000544A2 (pt) 2016-07-15 2019-04-24 Takeda Pharmaceutical Company Limited métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática
EP3487506A1 (en) 2016-07-20 2019-05-29 Hybrigenics SA Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
CN110997722B (zh) 2017-06-08 2023-09-26 黑带医疗有限公司 Cd38调节抗体
JP7679196B2 (ja) 2017-06-08 2025-05-19 ブラック ベルト セラピューティクス リミテッド Ｃｄ３８調節抗体
CN111032693B (zh) 2017-08-16 2023-09-26 黑带医疗有限公司 Cd38调节抗体
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
CA3072296A1 (en) * 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US20200207867A1 (en) 2017-09-13 2020-07-02 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
WO2019053613A2 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
CN111836642A (zh) 2017-10-25 2020-10-27 艾科赛扬制药股份有限公司 Alk7结合蛋白及其用途
CA3079242A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
KR20200076732A (ko) 2017-11-03 2020-06-29 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38-지시된 키메라 항원 수용체 작제물
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CN116731173A (zh) 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
AU2019208102B2 (en) 2018-01-12 2025-10-09 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-CD38 antibodies
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
PE20201265A1 (es) 2018-03-21 2020-11-19 Alx Oncology Inc Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
AU2019270624B2 (en) 2018-05-16 2024-05-02 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CA3103114A1 (en) * 2018-06-20 2019-12-26 Sorrento Therapeutics, Inc. Variant antibody that binds cd38
CA3106146A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
BR112021004130A2 (pt) 2018-09-11 2021-05-25 Jiangsu Hengrui Medicine Co., Ltd. anticorpo anti-cd38, fragmento de ligação ao antígeno do mesmo, e uso farmacêutico
CN109293773B (zh) * 2018-09-25 2020-09-04 上海邦耀生物科技有限公司 靶向cd38蛋白的抗体、嵌合抗原受体和药物
JP2022512722A (ja) 2018-10-17 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下投与を提供する方法
BR112021000173A2 (pt) 2018-10-26 2021-05-04 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd38
CA3117447C (en) 2018-11-13 2024-06-04 Janssen Biotech, Inc. Control of trace metals during production of anti-cd38 antibodies
EP3893841A1 (en) * 2018-12-14 2021-10-20 MorphoSys AG Antibody formulations
EP3914616A1 (en) * 2019-01-23 2021-12-01 Encefa Cd31 competitors and uses thereof
WO2020187718A1 (en) * 2019-03-15 2020-09-24 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
WO2021003074A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-cd38 antibody and methods of use thereof
JP2022548925A (ja) * 2019-09-18 2022-11-22 モメンタ ファーマシューティカルズ インコーポレイテッド ＣＤ３８を標的とした改変されたＦｃ抗原結合ドメイン構築物に関する組成物及び方法
TWI878355B (zh) 2019-10-02 2025-04-01 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之多重專一性結合蛋白
GB201916150D0 (en) 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
WO2021112196A1 (ja) * 2019-12-05 2021-06-10 学校法人東京薬科大学 筋組織の減少を抑制するための組成物
IL293751A (en) 2019-12-18 2022-08-01 Teneofour Inc Heavy chain antibodies binding to cd38
PE20230113A1 (es) 2020-01-16 2023-01-27 Genmab As Formulaciones de anticuerpos anti-cd38 y usos de las mismas
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
WO2021236658A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2022002065A1 (zh) * 2020-06-30 2022-01-06 百奥泰生物制药股份有限公司 抗cd40抗体或抗原结合片段及其应用
CN111808193B (zh) * 2020-06-30 2022-04-05 源道隆（苏州）医学科技有限公司 可结合人cd38的纳米抗体及其应用
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
AR123862A1 (es) 2020-10-21 2023-01-18 Boehringer Ingelheim Int Moléculas de unión biespecíficas anti-vegf y anti-trkb para el tratamiento de enfermedades oculares
JP2024503432A (ja) 2021-01-14 2024-01-25 モルフォシス・アーゲー 抗ｃｄ３８抗体及び抗ｃｄ３８抗体の使用
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
US12275798B2 (en) 2021-06-17 2025-04-15 Boehringer Ingelheim International Gmbh Tri-specific binding molecules
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
WO2023010031A1 (en) 2021-07-28 2023-02-02 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
MX2024005406A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38.
AU2022380722A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
CN116514974A (zh) * 2022-01-30 2023-08-01 百奥泰生物制药股份有限公司 抗cd28抗体及其应用
EP4472740A1 (en) 2022-01-31 2024-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
PE20250669A1 (es) 2022-07-15 2025-03-04 Boehringer Ingelheim Int Moleculas de union para el tratamiento del cancer
WO2024094660A1 (en) 2022-10-31 2024-05-10 Genmab A/S Cd38 antibodies and uses thereof
AU2023375177A1 (en) 2022-11-02 2025-06-19 Janssen Biotech, Inc. Methods of treating cancers
AU2024208858A1 (en) 2023-01-20 2025-06-19 Boehringer Ingelheim International Gmbh Il-12 fc fusion proteins
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
CN119119277B (zh) * 2024-10-24 2025-09-09 深圳技术大学 一种靶向cd38的纳米抗体、药物组合物及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS63502112A (ja) * 1986-01-03 1988-08-18 コンソリデイテツド・フアーマシユーテイカルズ・リミテツド メルファラン誘導体
SU1595902A1 (ru) * 1988-06-30 1990-09-30 Всесоюзный онкологический научный центр АМН СССР Штамм гибридных культивируемых клеток животных MUS мUSсULUS L, используемый дл получени моноклональных антител к антигену СД38 кортикальных тимоцитов
US5156951A (en) * 1989-07-13 1992-10-20 Becton Dickinson And Company Detecting immunological changes in HIV infected patient samples
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
WO1994017184A1 (en) 1993-01-29 1994-08-04 Schering Corporation Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
US6555324B1 (en) 1993-11-04 2003-04-29 Becton Dickinson & Company Method to distinguish hematopoietic progenitor cells
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
JP4173539B2 (ja) 1995-05-11 2008-10-29 ラボラトアール・セローノ・ソシエテ・アノニム Ｉｌ−６活性阻害剤
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US5594116A (en) 1995-11-08 1997-01-14 Promega Corporation Tryptase polyclonal antibody and purification method for use in human tryptase immunoassay
JP4233608B2 (ja) * 1996-10-15 2009-03-04 塩野義製薬株式会社 自己抗体測定方法
JP2003524587A (ja) 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB9903664D0 (en) 1999-02-17 1999-04-14 Isis Innovation Adjuvant and cell maturation agent
JP2000316578A (ja) 1999-05-12 2000-11-21 Bml Inc 糖尿病発症危険因子の検出方法
EP1990409A3 (en) 1999-07-20 2011-05-18 MorphoSys AG Bacteriophage
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20020028488A1 (en) 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US6955884B2 (en) 2000-10-17 2005-10-18 Trudeau Institute, Inc. Methods for identifying compounds that inhibit CD38 activity
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
US6892140B1 (en) 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
WO2002059263A2 (en) 2000-12-19 2002-08-01 Sunol Molecular Corporation Transgenic animals comprising a humanized immune system
US20040081981A1 (en) 2001-01-31 2004-04-29 Toru Egashira Method of detecting risk factor for onset of diabetes
US7091323B2 (en) 2001-04-24 2006-08-15 Bayer Corporation Human TIMP-1 antibodies
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1369431A4 (en) 2001-10-15 2005-01-12 Kirin Brewery ANTI-HLA-DR ANTIBODIES
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7553926B2 (en) 2002-04-23 2009-06-30 Andrea Savarino Compositions containing anti-HIV peptides and methods for use
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
WO2005042019A1 (en) 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
EP1716176B1 (en) 2004-02-13 2009-10-21 Boehringer Ingelheim Pharmaceuticals, Inc. Cd38 splice variant and uses thereof
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
JP2008535853A (ja) 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌関連遺伝子
AR053489A1 (es) 2005-05-24 2007-05-09 Morphosys Ag Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
JP5362359B2 (ja) * 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
SI2205727T1 (sl) 2007-10-01 2015-09-30 Codexis, Inc. Polipeptidi ketoreduktaze za izdelavo azetidinona
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
LT2621531T (lt) * 2010-09-27 2017-04-10 Morphosys Ag Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HUE036518T2 (hu) * 2012-09-25 2018-07-30 Morphosys Ag Kombinációk és alkalmazásaik
DK2914302T3 (en) * 2012-11-05 2017-04-10 Morphosys Ag RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
WO2020202527A1 (ja) 2019-04-04 2020-10-08 オリンパス株式会社 画像記録装置
US12491218B2 (en) 2019-06-30 2025-12-09 Uplift Food Inc Prebiotic and probiotic cookie preparation
US11920830B1 (en) 2022-11-11 2024-03-05 Russell Dwayne Mcnally Tool and method for cleaning and draining a water heater

Also Published As

Publication number Publication date
BRPI0618399B1 (pt) 2023-10-03
NO20081972L (no) 2008-04-25
US11939395B2 (en) 2024-03-26
US20240309109A1 (en) 2024-09-19
NZ566915A (en) 2011-09-30
KR101574920B1 (ko) 2015-12-04
IL190665B (en) 2018-06-28
KR20150139636A (ko) 2015-12-11
PL2860192T3 (pl) 2018-03-30
JP2009511033A (ja) 2009-03-19
EP2860192A2 (en) 2015-04-15
AR055191A1 (es) 2007-08-08
KR101472250B1 (ko) 2014-12-11
LT2860192T (lt) 2017-12-11
US20120052078A1 (en) 2012-03-01
ME02886B (me) 2018-04-20
BRPI0618399A2 (pt) 2011-08-30
HUE035250T2 (hu) 2018-05-02
SI2860192T1 (en) 2018-04-30
TW200730624A (en) 2007-08-16
CA2625681A1 (en) 2007-04-19
WO2007042309A2 (en) 2007-04-19
US10184005B2 (en) 2019-01-22
KR20080068056A (ko) 2008-07-22
JP5362359B2 (ja) 2013-12-11
RU2425841C2 (ru) 2011-08-10
WO2007042309A3 (en) 2007-09-13
CY1119722T1 (el) 2018-06-27
EP2860192A3 (en) 2015-04-22
EP2860192B1 (en) 2017-09-27
SG10201400973XA (en) 2014-08-28
US11059902B2 (en) 2021-07-13
CN103554259B (zh) 2016-05-18
CN101287764B (zh) 2013-11-13
HRP20171978T1 (hr) 2018-04-06
EP1945671A2 (en) 2008-07-23
EP3284756A1 (en) 2018-02-21
ES2653664T3 (es) 2018-02-08
US20090252733A1 (en) 2009-10-08
KR20140022427A (ko) 2014-02-24
CN103554260A (zh) 2014-02-05
AU2006301446A1 (en) 2007-04-19
RS56677B1 (sr) 2018-03-30
CN106434683A (zh) 2017-02-22
US20130273072A1 (en) 2013-10-17
EP3284756B1 (en) 2021-05-05
US8486394B2 (en) 2013-07-16
PT2860192T (pt) 2017-12-26
AR105490A2 (es) 2017-10-11
CN106434683B (zh) 2020-03-13
DK2860192T3 (en) 2018-01-02
IL190665A0 (en) 2008-11-03
RU2008111882A (ru) 2009-11-20
KR20140105029A (ko) 2014-08-29
US20210292431A1 (en) 2021-09-23
HK1194398A1 (zh) 2014-10-17
CN101287764A (zh) 2008-10-15
US8088896B2 (en) 2012-01-03
CA2625681C (en) 2016-08-02
JP5752667B2 (ja) 2015-07-22
CN103554259A (zh) 2014-02-05
NO344961B1 (no) 2020-08-03
AU2006301446B2 (en) 2012-06-07
US9193799B2 (en) 2015-11-24
TWI428444B (zh) 2014-03-01
KR101512853B1 (ko) 2015-04-28
US20160075796A1 (en) 2016-03-17
JP2013079238A (ja) 2013-05-02
HK1122822A1 (en) 2009-05-29
US20190077877A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
IL190665A0 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
IL225386A0 (en) Diagnosis and treatment of cancer using anti-ereg antibody
PL1951273T3 (pl) Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych
IL183458A0 (en) Anti-il-1r1 single domain antibodies and therapeutic uses
IL231169A0 (en) Human monoclonal antibodies to fucosil - 1gm and methods of using antibodies against fucosil - 1gm
EP1948298A4 (en) BIO-INTERVENING THERAPEUTIC TREATMENT FOR HEART DISEASE DISEASES
IL193747A0 (en) New therapeutic combinations for the treatment of depression
PT2056842E (pt) Galactosil-ceramidas modificadas para coloração e estimulação de células t assassinas naturais
PL2631241T3 (pl) Sposób generowania białka i jego zastosowanie
IL185097A0 (en) Tissue specific expression of antibodies in chickens
EP1868679A4 (en) THERAPY EXERCISING NON-IMMEDIATE EFFECTS
ZA200703884B (en) S-mirtazapine for the treatment of hot flush
ZA200802935B (en) Use of lactobacillus for treatment of autoimmune diseases
PL1913946T3 (pl) Środek terapeutyczny oraz sposób leczenia do złagodzenia mocznicy
SI2301576T1 (sl) Terapevtska uporaba protiteles proti CS1
IL185900A0 (en) Compositions and methods for the diagnosis and treatment of tumor
ZA200802541B (en) Human antibodies against IL13 and therapeutic uses
GB0501490D0 (en) Therapeutic infrasound generator and amplifier for clinical application
IL198479A0 (en) Methods for screening for therapeutic molecules and use of the molecules therefrom
ZA200706159B (en) Compositions and methods for the diagnosis and treatment of tumor
HK1132512A (en) Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers
GB0602168D0 (en) Therapeutic preparations for the therapy of dermatoses
GB0417867D0 (en) Treatment of pipes
GB0605738D0 (en) Novel diagnostic and therapeutic methods